Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 19;10(9):1203.
doi: 10.3390/biom10091203.

Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis

Giovanni Pallio  1 , Federica Mannino  1 , Natasha Irrera  1 , Ali H Eid  2 , Francesco Squadrito  1 , Alessandra Bitto  1
Affiliations
Review

Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis

Giovanni Pallio et al. Biomolecules. .

Abstract

Rheumatoid arthritis (RA) is a systemic disease that leads to joint destruction. During the last decade, the therapy of RA has been principally based on biological drugs. Although the efficacy of biological therapy has been established, patients demonstrated a high heterogeneity in clinical response to treatment. Several genetic polymorphisms play a part in the different response to biological drugs. This review summarizes the pharmacogenetics of biological agents approved for clinical RA treatment. We reviewed PubMed papers published over the past 20 years (2000-2020), inserting as the search term "rheumatoid arthritis and polymorphisms". Despite some studies showing important correlations between genetic polymorphisms and response to biological therapy in RA patients, most of these findings are still lacking and inconsistent. The personalized treatment according to a pharmacogenetics approach is promising but the available pharmacogenetics data on biological treatment in RA are not adequate and reliable to recommend pharmacogenetic tests before starting biological therapy in RA patients.

Keywords: CD20; CD80; CD86; IL-1; IL-6; TNF-α; polymorphism; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Hunter T.M., Boytsov N.N., Zhang X., Schroeder K., Michaud K., Araujo A.B. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatol. Int. 2017;37:1551–1557. doi: 10.1007/s00296-017-3726-1. - DOI - PubMed
    1. Carlens C., Hergens M.-P., Grunewald J., Ekbom A., Eklund A., Höglund C.O., Askling J. Smoking, Use of Moist Snuff, and Risk of Chronic Inflammatory Diseases. Am. J. Respir. Crit. Care Med. 2010;181:1217–1222. doi: 10.1164/rccm.200909-1338OC. - DOI - PubMed
    1. Scott D.L., Steer S. The course of established rheumatoid arthritis. Best Pr. Res. Clin. Rheumatol. 2007;21:943–967. doi: 10.1016/j.berh.2007.05.006. - DOI - PubMed
    1. Scott D.L., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet. 2010;376:1094–1108. doi: 10.1016/S0140-6736(10)60826-4. - DOI - PubMed
    1. Choy E.H.S., Isenberg D.A., Garrood T., Farrow S., Ioannou Y., Bird H., Cheung N., Williams B., Hazleman B., Price R., et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002;46:3143–3150. doi: 10.1002/art.10623. - DOI - PubMed

Publication types

MeSH terms

Substances